Abstract
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in the prostate gland and prostate cancer. PSMA has been recently used in positron emission tomography/computed tomography (PET/CT) imaging and targeted alpha-radiation therapy (TAT) for prostate cancer. Recently, the tubarial gland, a type of minor salivary gland that is described as a new organ situated in the pharynx, is reported to express PMSA. Here, we studied the expression of PSMA in common benign and malignant salivary gland tumors. We performed immunohistochemistry for PSMA in 55 salivary gland tumors comprising 10 pleomorphic adenomas, 10 Warthin tumors, 9 basal cell adenomas, 9 adenoid cystic carcinomas, 9 mucoepidermoid carcinomas, and 8 salivary duct carcinomas. PSMA was expressed in 97% of benign tumors and 77% of malignant tumors. Moreover, PSMA was expressed in 59% of normal salivary glands adjacent to the tumor. PSMA is relatively expressed in salivary gland tumors and salivary glands. Therefore, salivary gland neoplasm, and normal salivary gland, possibly demonstrate the accumulation of PSMA in PET/CT. Thus, we need to monitor the side effects in the salivary glands during TAT for prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Data available on request from the corresponding author.
References
Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, et al. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. BMC Cancer. 2020;20:723.
Tateishi U. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Jpn J Clin Oncol. 2020;50:349–56.
Czerwińska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules. 2020;25:1743.
Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016;50:345–54.
Valstar MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, Smit LA, Klein Nulent TJW, et al. The tubarial salivary glands: a potential new organ at risk for radiotherapy. Radiother Oncol. 2021;154:292–8.
Iwanaga J, Ibaragi S, Nakano K, Takeshita Y, Tubbs RS. No convincing evidence for the presence of tubarial salivary glands: a letter to the editor regarding “The tubarial salivary glands: a potential new organ at risk for radiotherapy.” Radiother Oncol. 2021;154:321–2.
Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma- a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017;44:1614–21.
Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Sood A, et al. 68Ga-labelled PSMA (prostate specific membrane antigen) expression in signet-ring cell gastric carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:1276–7.
Arçay A, Eiber M, Langbein T. Incidental finding of colon carcinoma related to high uptake in 18F-PSMA-1007 PET. Clin Nucl Med. 2020;45:561–2.
Soeda F, Watabe T, Kato H, Uemura M, Nonomura N. Duodenal adenocarcinoma mimicking metastasis of prostate cancer on 18F-prostate-specific membrane Antigen-1007 PET/CT. Clin Nucl Med. 2021;46:49–51.
Sirtl S, Todica A, Ilhan H, Zorniak M, Bartenstein P, Mayerle J. Incidental finding of a PSMA-positive pancreatic cancer in a patient suffering from a metastasized PSMA-positive prostate cancer. Diagnostics (Basel). 2021;11:129.
Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44:702–6.
Bertagna F, Albano D, Giovanella L, Bonacina M, Durmo R, Giubbini R, et al. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens). 2019;18:145–9.
Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, et al. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET/CT: Exploring new theranostic avenues. Clin Nucl Med. 2018;43:359–60.
Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21:799–807.
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527–32.
Chakravarty R, Siamof CM, Dash A, Cai W. Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. Am J Nucl Med Mol Imaging. 2018;8:247–67.
Funding
Not applicable
Author information
Authors and Affiliations
Contributions
HN summarized this paper. YK, TK, HK, and TD checked all research progress and the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Not applicable
Ethical Approval
The study is approved by the institutional ethics committee (approval number: 2096).
Consent to Participate
The study is retrospective and the patriciate’s consent is obtained through opt-out.
Consent for Publication
Approve.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nishida, H., Kondo, Y., Kusaba, T. et al. Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors. Head and Neck Pathol 16, 427–433 (2022). https://doi.org/10.1007/s12105-021-01376-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12105-021-01376-8